drugset / Trial / NCT07074418
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Phase 4
Not yet recruiting
34 enrolled
Centre Hospitalier Universitaire de Nice
Boehringer Ingelheim · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
Timeline
- Start
- 2026-04
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 10 mg | — |